Neurocrine Biosciences, Inc. (NBIX) Stock: Pessimism is a stepping stone to opportunity

Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]

Neurocrine Biosciences, Inc. (NBIX) Stock deserves your attention

Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]

Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock rose 23.08% in Last Six Months?

Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]

Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock Jumped 1.32% in Last Month?

Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]

Why Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock up 3.29% in Last Week?

Citigroup raised the price target for the Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stock to “a Neutral”. The rating was released on December 13, 2023, according to finviz. The research report from Cantor Fitzgerald has resumed the stock to Overweight, with a price target set at $140. The stock was reiterated by Mizuho, who disclosed in a […]